ArticleJournal of general internal medicine2026
National Trends in HIV Pre-Exposure Prophylaxis Dispensing to Young Adults, 2016-2023.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundU.S. young adults account for a disproportionate share of new HIV diagnoses. Despite this, no national study has examined recent trends in HIV pre-exposure prophylaxis (PrEP) dispensing to this age group.
objectiveTo assess trends in PrEP dispensing to young adults from 2016 to 2023.
designCross sectional study of the IQVIA Longitudinal Prescription Database.
participantsYoung adults aged 18-25 years. MAIN MEASURES: Quarterly PrEP dispensing rate (number of young adults with dispensed PrEP prescriptions per 100,000 U.S. young adults), quarterly PrEP initiation rate (number of young adults with a new dispensed PrEP prescription per 100,000 U.S. young adults), and quarterly mean PrEP persistence (number of days with an active PrEP prescription in the 180 days after the new PrEP prescription ended among those initiating therapy). Joinpoint regression was used to identify slope changes and calculate the quarterly percent change (QPC). Subgroup analyses were conducted by age group. KEY
resultsAnalyses included 1,450,296 PrEP prescriptions dispensed between January 1, 2016-December 31, 2023 to 239,780 young adults. The quarterly PrEP dispensing rate increased sharply between 2016-2018, from 26.4 to 100.7 prescriptions per 100,000 people (QPC: 12.5%, 95% CI: 10.0 to 15.1). Afterwards, this rate increased gradually to 208.4 prescriptions per 100,000 people in 2023 (QPC: 3.5%, 95% CI: 2.7 to 4.3). Trends in the quarterly PrEP initiation rate were qualitatively similar. From 2016 to 2023, quarterly mean persistence decreased from 111.6 to 98.4 days (QPC: -0.4%, 95% CI: -0.6, -0.2). Compared with patients aged 22-25 years, those aged 18-21 years had lower quarterly PrEP dispensing and initiation rates throughout 2016-2023. Persistence was lower in these younger patients in 2016, but the gap narrowed over time.
conclusionsDispensing and initiation of PrEP among young adults is increasing, but treatment episodes are shortening. Efforts to promote retention in therapy are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.